Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer

Trial Profile

A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Ivonescimab (Primary) ; Ligufalimab (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Akeso Biopharma

Most Recent Events

  • 27 Feb 2025 Number of treatment arms are increased from 6 to 11 by the addition of 5 more experimental treatment arms, namely- Expansion Stage Group C, D, E, F and G, Part 2 cohort 1 and Part 2 cohort 2.
  • 27 Feb 2025 Planned number of patients changed from 104 to 254.
  • 27 Feb 2025 Planned End Date changed from 25 Dec 2026 to 12 Aug 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top